HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

France’s Health Product Safety Agency recommends to Directorate General for Health that aluminum in cosmetics be limited to 0.6%. GlaxoSmithKline and Colgate-Palmolive settle their feud over rights to the “nurdle” toothpaste icon. More news in brief.

You may also be interested in...



Navigating The Beauty Box Craze: The Players And The Potential

Beauty boxes enable firms to increase brand awareness and reach key demographics while tracking where samples go, how they are received and whether they translate to sales. Euromonitor International Research Analyst Rachel Lin offers pointers on how to make the most of the beauty-box experience.

Not Your Mother’s Hair Care Grows On Punchy Packaging, YouTube Activity

YouTube and other online social media helped propel Not Your Mother’s hair care in its first year, from college bookstores and about 300 Walmart locations to more than 1,500 Walmart doors and all ULTA Beauty destinations nationwide.

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel